Schaeffer A H, Greene H L, Reid P R
Am J Cardiol. 1978 Dec;42(6):1007-12. doi: 10.1016/0002-9149(78)90689-6.
The repetitive ventricular response, defined as the production of two or more ventricular premature complexes in response to a single ventricular pacing stimulus, is common in patients with serious ventricular arrhythmias. Twenty-seven patients with refractory ventricular tachycardia were studied to determine whether acute suppression of the repetitive ventricular response by aprindine predicts long-term effectiveness of this agent. Twenty-three of the 27 patients had the repetitive ventricular response before intravenous administration of aprindine, whereas only 6 had the response after aprindine. All patients were maintained on a regimen of oral aprindine and evaluated repeatedly for a mean of 12 months. Twenty of the 21 patients who had no repetitive ventricular response after intravenous aprindine manifested clinical improvement compared with only 1 of the 6 in whom the repetitive response was present after aprindine (P less than 0.0005). Aprindine is a useful agent in refractory ventricular tachycardia, and the absence of the repetitive ventricular response after its intravenous administration predicts long-term clinical responsiveness to the oral form.
重复心室反应定义为对单个心室起搏刺激产生两个或更多室性早搏复合波，在严重室性心律失常患者中很常见。对27例难治性室性心动过速患者进行研究，以确定阿普林定对重复心室反应的急性抑制是否可预测该药物的长期疗效。27例患者中有23例在静脉注射阿普林定前有重复心室反应，而注射后只有6例有此反应。所有患者均维持口服阿普林定治疗方案，并平均反复评估12个月。静脉注射阿普林定后无重复心室反应的21例患者中有20例表现出临床改善，而阿普林定后仍有重复反应的6例患者中只有1例有改善（P小于0.0005）。阿普林定是治疗难治性室性心动过速的有效药物，静脉注射后无重复心室反应可预测对口服制剂的长期临床反应性。
